Skip to main content
OpenTrials
Completed

NCT Number: NCT04571125

Multimodal Neurobiological Approaches to Explore the Gene-Environment Interactions in ADHD

Previous studies have demonstrated significant associations of attention-deficit hyperactivity disorder (ADHD) with monoamine transporter genes, including dopamine transporter gene (DAT1), norepinephrine transporter gene (SLC6A2), and serotonin transporter gene (SLC6A4) as well as the important role of environmental factors in the pathogenesis of ADHD. Hence, investigating how genes and environments interact with each other may contribute to the understanding of the pathophysiological mechanisms of ADHD. In this 3-year project, investigators will explore the complex gene-environment interplay in ADHD with multimodal neurobiological approaches, including neuropsychology, neuroimaging, and metabolites, in order to identify the crucial pathophysiological pathways from genes to the brain.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Monoamine Transporter Genes Environmental Factors

Age range

7 year–16 year

Sex eligibility

All sexes

Study type

Observational

Primary location

National Taiwan University Hospital, Taipei, Taiwan

Loading trial locations.

About this study

In the present project, investigators aim to explore the complex gene-environment interplay in children with ADHD to identify the crucial pathophysiological pathways from genes to the brain. To achieve our objective, investigators will use multimodal neurobiological approaches to effectively resolve the four major challenges in exploring gene-environment interactions on ADHD.

  • investigators will use multiple levels of neurobiological approaches to identify the interactions between monoamine transporter genes and environment on ADHD, including neuropsychology, neuroimaging, and neuroactive metabolites in plasma, which will provide larger effects than clinical diagnosis.
  • investigators will employ correlation analyses to test for the presence of correlations between the monoamine transporter genotypes and the environmental factors.
  • investigators will use both categorical (diagnosis of ADHD) and dimensional (inattention and hyperactivity-impulsivity symptoms of ADHD) approaches to assess the interaction effects between monoamine transporter genes and environment.
  • investigators will conduct interactions with ageitems to model more accurately the effects of age, which may be non-linearly related to the neurobiological basis of ADHD.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Children or adolescents, between 7 and 16 years of age, must have clinical diagnosis of ADHD according to the DSM-5 diagnostic criteria.
  • They have to be medication-naïve. They never receive any medication for the treatment of ADHD.
  • They and their parents must understand sufficiently to communicate properly with the investigators.
  • They must have a Full-Scale Intelligence Quotient(FIQ) score greater than 80.

Exclusion criteria

  • They have a major psychiatric comorbid disorder, including schizophrenia, schizoaffective disorder, affective disorders, or autism spectrum disorder.
  • They have a past history of seizure, or they are taking antiepileptic drugs.
  • They have a past history of substance dependence or abuse, including nicotine, alcohol, amphetamine, or any over-the-counter medication.
  • They have a past history of major systemic disease.
  • They are using Chinese herbs or health supplements.

Treatment and study plan

Primary outcomes

  1. ADHD symptoms

    Time frame: 1 hour

    Subjects will be interviewed by Chinese Version of the Kiddie Epidemiologic version of the Schedule for Affective Disorders and Schizophrenia (K-SADS-E)

Secondary outcomes

  1. Neuropsychological testing

    Time frame: 1.5 hours

    Subjects will be assessed by the Cambridge Neuropsychological Test Automated Battery (CANTAB)

  2. Neuropsychological testing

    Time frame: 15 mins

    Subjects will be assessed by the Continuous Performance Test

  3. Metabolomics profiling

    Time frame: 10 mins

    All the biomarkers are relative ratios. Although all the names of metabolites examined in this study cannot be listed due to the upper limitation of word number (999 characters), the metabolomics profiling includes Hydroxybutyric acid, Undecanedicarboxylic acid, Methyladenosine, Hydroxybutyric acid, Furoylglycine, Hydroxy, Hydroxybutyric acid, Hydroxycaproic acid,Oxoglutarate, Hydroxyisovaleric acid, Hydroxymethylglutaric acid,Indolepropionic acid, Methyladenine, Methylhistidine, Methylindole, Methylxanthine, Pyridylacetic acid, Guanidinobutanoic acid, Dihydrothymine, Aminolevulinic acid, Dodecenoic acid, Hydroxylysine P66-59, Methylcytidine, Acetoacetic acid, Acrylamide, Allose, AMP, Androstenedione, Aspartic acid, Betaine, Bradykinin, Carnitine, Cholic Acid, cis-Aconitate, cis-Fenpropimorph, citric acid, Corticosterone, Creatine, Creatinine, D-Arginine, Decanoylcarnitine, Dehydroascorbic acid, Deoxycholic acid, Deoxyribose, etc.

  4. Brain imaging

    Time frame: 1 hour

    Subjects will be assessed by structural and functional brain imaging, including xoxel-based morphometry, diffusion spectrum imaging, resting-state fMRI, and counting Stroop task fMRI

Sponsors and collaborators

Lead sponsor

National Taiwan University Hospital

Other

Registry information

Official study title

A Study With Multimodal Neurobiological Approaches to Explore the Interactions Between Monoamine Transporter Genes and Environmental Factors on Attention Deficit Hyperactivity Disorder.

Important dates

Study start
2020
Primary completion
2023
Study completion
2023
First posted
Sep 30, 2020
Registry last updated
Mar 19, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.